NPS Bowel Drug Gattex’s Risk Plan Gains FDA Staff Support

NPS Pharmaceuticals Inc.’s plan to manage the risks of Gattex, a drug for patients who have lost the ability to absorb nutrients, gained the support of U.S. regulators in a report.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.